A Study of STM-416 Administered to Patients Undergoing TURBT for Recurrent Bladder Cancer
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: STM-416.
- Who it may be relevant to
- Registry conditions: Non-muscle-invasive Bladder Cancer. Basic parameters: from 18 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- United States
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
A Phase 1/2a Study of STM-416 Administered Intraoperatively to Patients Undergoing Transurethral Resection of Bladder Tumor (TURBT) for Recurrent High-Grade Papillary Bladder Cancer
Overview
This is a first-in-human (FIH), Phase 1/2a, multi center, open-label, single treatment, dose escalation and expansion study designed to determine the safety and tolerability of STM-416 in patients with bladder cancer.
Detailed description
This is a 2-part, multicenter, first-in-human (FIH), Phase 1/2a study in patients with a history of pathologically confirmed high-grade Ta or T1 NMIBC without CIS who have completed SOC previously, with recurrent papillary disease seen on cystoscopy, and who are undergoing TURBT without perioperative intravesical chemotherapy. All patients will receive relevant SOC therapy following TURBT. SOC will be administered in the adjuvant setting.
Phase 1 is an open-label, single-treatment, dose-escalation study to evaluate the safety and tolerability of up to 6 increasing doses of intraoperatively administered STM-416 utilizing a 3+3 convention, with 3 to 6 patients enrolled in each STM-416 dose level, with a minimum of 6 patients enrolled at the highest dose level, for a total of approximately 30 patients.
Phase 2a is a randomized, single-blind, single-treatment, dose-expansion study that will comprise 2 arms: TURBT + STM-416 Dose 1 followed by SOC versus TURBT + STM-416 Dose 2 followed by SOC.
Interventions
- Drug STM-416
STM-416 monotherapy
Primary outcome measures
- Incidence of dose-limiting toxicities (DLTs) [Safety and Tolerability] Phase 1 [Time frame: 21 days]
- Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability] Phase 1 [Time frame: Time on trial up to 90 days]
- Recurrence free survival time (Phase 2a) [Time frame: Through study completion up to 24 months]
Secondary outcome measures (3)
- Pharmacokinetics of STM-416 (Phase 1) [Time frame: Day 0, post 24 hours, post 48 hour]
- Pharmacokinetics of STM-416 (Phase 1) [Time frame: Day 0, post 24 hours, post 24 hour]
- Pharmacodynamics of STM-416 [Time frame: Day 0, post 24 hours, post 48 hours, post 21 days, post 90 days]
Eligibility criteria
Inclusion criteria
- Are aged 18 years or older;
- Have a history of pathologically confirmed high-grade Ta or T1 NMIBC without CIS who have completed SOC previously, with recurrent papillary disease seen on cystoscopy, and who are undergoing TURBT without perioperative intravesical chemotherapy;
- Are considered high risk for recurrence;
- Have Eastern Cooperative Oncology Group (ECOG) Performance Status of 0, 1, or 2;
- Have adequate organ and marrow function as defined below:
- Hemoglobin 9.0 g/dL;
- Absolute neutrophil count 1.5 × 109/L (1500 per mm3);
- Platelet count 75 × 109/L (75,000 per mm3);
- Serum bilirubin 1.5 × institutional upper limit of normal (ULN);
- AST (serum glutamic-oxaloacetic transaminase)/ALT (serum glutamic-pyruvic transaminase) 2.5 × institutional ULN; and
- Creatinine CL 60 mL/min by the Cockcroft-Gault formula or by 24-hour urine collection for determination of creatinine CL: Males: Creatinine CL (mL/min) = Weight (kg) × (140 - Age)/72 × serum creatinine (mg/dL); or Females: Creatinine CL (mL/min) = Weight (kg) × (140 - Age) × 0.85/72 × serum creatinine (mg/dL).
Exclusion criteria
- Have a history of CIS or MIBC;
- Are receiving any other investigational agents;
- Have a history of allergic reactions attributed to compounds of similar chemical or biologic composition to resiquimod (R848), or excipients used in STM-416 including poloxamer 407 and sodium hyaluronate;
- Have an uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.
Urinary tract infections are not exclusionary unless they are NCI-CTCAE Grade 3 or higher;
- Are a woman of childbearing potential regardless of contraceptive use; Note: Women of childbearing potential are only to be excluded in Phase 1 and Phase 2a to avoid bias due to the low prevalence of NMIBC in this population. However, they will be included in subsequent Phase 2/3 studies.
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Allocation
- N/A
- Model
- Single group
- Masking
- Open label
- Primary purpose
- Treatment
Study locations
United States · 20 centers
- East Valley Urology Center of Arizona — Mesa
- Arizona Urology Specialists — Tucson
- Arkansas Urology — Little Rock
- Unio Specialty Care - A Genesis Healthcare Partners Facility — Bakersfield
- Genesis Research — Downey
- Urology Center of Southern California — Murrieta
- Advanced Urology Institute — Daytona Beach
- University of Florida — Gainesville
- … and 12 more centers
Identifiers
NCT: NCT05710848 · STM-416-01